• Alexza Pharmaceuticals Inc., of Mountain View, Calif., said in a registration statement filed with the Securities and Exchange Commission that it plans to sell up to $75 million of its common stock. The company also said it has executed a $15 million working capital loan agreement with Hercules Technology Growth Capital to be used for capital equipment and working capital. In connection with the loan, Alexza issued Hercules warrants to purchase 376,394 shares of common stock at an exercise price of $2.69 per share. The company's compound AZ-004 (Staccato loxapine) has an FDA action date of Oct. 11.

• International Stem Cell Corp., of Oceanside, Calif., entered a definitive agreement with Socius CG II Ltd. in which Socius committed to purchase a single tranche of up to $10 million in nonconvertible Series F preferred stock. The company issued a warrant to purchase $13.5 million worth of common stock, with the exercise price to be determined. Proceeds will be used to provide general working capital and to fund additional development of the company's Parthenogenetic Stem Cell Lines, development of commercial research products and other research and development programs.

• Mylan Inc., of Pittsburgh, said in a Securities and Exchange Commission filing that it intends to privately place $1 billion in principal amount of senior notes due 2017 and 2020. The net proceeds are expected to be used by Mylan to prepay a portion of its outstanding term loans.